Table 4.
Cardiac, clinical and global outcomes
| Event | Total (n = 40) |
|---|---|
| Death during Impella 5.0 support, n (%) | 12 (30) |
| Impella 5.0 weaning, n (%) | 18 (45) |
| Sustained cardiac recoverya at ICU discharge, n (%) | 16 (40) |
| Bridge to LVAD, n (%) | 9 (23) |
| Bridge to heart transplantation, n (%) | 3 (8) |
| Total MV duration, days [IQR] | 15 [7–26] |
| Need for RRT in ICU, n (%) | 17 (43) |
| ICU length of stay, days [IQR] | 20 [8–32] |
| Mortality at day 28, n (%) | 14 (35) |
| Post-AMI, n (%) | 9 (53 %) |
| Dilated cardiomyopathy, n (%) | 3 (25 %) |
| Postcardiotomy, n (%) | 1 (14 %) |
| Others, n (%) | 1 (25 %) |
| Mortality at ICU discharge, n (%) | 17 (43) |
| Mortality at month 6, n (%) | 20 (50) |
ICU intensive care unit, LVAD left ventricular assist device, MV mechanical ventilation, IQR interquartile range, RRT renal replacement therapy, AMI acute myocardial infarction
aDefined by ICU discharge without inotropes or mechanical circulatory support or transplant